Federal fetal tissue research ban narrows medical research pathway
H.R. 2075 — Protecting Life and Integrity in Research Act of 2025 · Filed by Robert Onder (R-MO) · 33 cosponsors · Introduced Mar 11, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits the federal government from conducting, funding, or supporting research using human fetal tissue obtained from induced abortions. It permits research on fetal tissue from miscarriages or stillbirths, and allows development of alternative cell lines not derived from aborted fetal tissue. It also bars federal agencies from knowingly acquiring or accepting donations of tissue from induced abortions.
Why we flagged it
The bill's core function is to restrict federal research using fetal tissue from induced abortions while permitting research on tissue from natural fetal loss. This is a substantive policy choice on a contentious moral and scientific question, not a technical amendment or narrow carve-out.
What the text implies
- Eliminates a research pathway that has contributed to vaccine development and genetic vector research; may slow or redirect medical research programs relying on this tissue source.
- Creates a definitional boundary (induced abortion vs. miscarriage/stillbirth) that may complicate tissue sourcing and institutional compliance, particularly in cases of ambiguous or incomplete medical records.
- Repeals section 113 of the National Institutes of Health Revitalization Act of 1993, which previously governed fetal tissue research; the full scope of that repeal depends on what section 113 contained.
- Aligns federal law with state-level abortion restrictions in some jurisdictions, potentially creating pressure on researchers in states with different abortion policies.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill restricts a research avenue that some citizens view as ethically problematic (using tissue from induced abortions) and aligns law with pro-life values; however, it also eliminates a potential source of medical research that other citizens and the medical community view as valuable for treating disease, creating a genuine trade-off between competing moral and scientific interests.
Named in the bill
Federal government, National Institutes of Health, Public Health Service Act (section 498A, 498B), National Institutes of Health Revitalization Act of 1993, Title 18, United States Code (section 1841)
Where it stands
33 cosponsors: 33 Republicans.
- Mar 11, 2025 — Introduced · Congress.gov: “Introduced in House”
- Mar 11, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 3 disclosure filings across 3 quarters, Mar 2025 to Sep 2025. Those filings disclosed $1,450,000 in lobbying spend. A filing names 35 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Robert Onder, the sponsor, reported $483,750 in PAC receipts in the 2026 cycle.
- Susan B Anthony List — $1,450,000 on 3 filings
Lobbying Disclosure Act filings through Oct 20, 2025. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (3,835 characters) on Nov 14, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Mar 2025 to Sep 2025. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 20, 2025 · page rendered 2026-11-22.
“Federal fetal tissue research ban narrows medical research pathway” QuorumCivic. https://share.quorumcivic.app/bill/119/hr2075 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.